Divyesh Maru appointed CFO of Hester Biosciences
He specializes in financial planning, audit, compliance and ERP implementation, with extensive experience in leading automation and risk management projects
He specializes in financial planning, audit, compliance and ERP implementation, with extensive experience in leading automation and risk management projects
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Q2 FY25 Total Income was at Rs. 85.4 crore
Hospital business revenues increase 13.9% to Rs. 1,655 crore
Subscribe To Our Newsletter & Stay Updated